red blood cell transfusionsurvivaltransfusion intensityTransfusion is an integral part of supportive care in patients undergoing aggressive chemotherapy for acute myeloid leukemia (AML). As transfusion induces immune modulation, the objective of the study was to assess whether the intensity of red blood ...
Acute myeloid leukemia (AML) is a type of blood cancer that starts in your bone marrow, which is the soft inner part of your bones where all your blood cells are made. AML usually begins in cells that turn into white blood cells but can also start in other blood-forming cells. When b...
Elderly (especially over age 75) patients have special treatment concerns. They may be less able to tolerate the septicemia (blood poisoning) associated with loss of granulocytes and they often have higher rates of myelodysplastic (’pre-leukemia’) syndrome (MDS). High dose chemo is unlikely to...
Acute Myeloid Leukemia (AML) is a bone marrow malignancy characterized by the infiltration of the bone marrow, blood and other tissues by clonal cells of the myeloid lineage with limited or no potential for differentiation [1]. From:Leukemia Research,2022 ...
Progress in the understanding of the biology and therapy of acute myeloid leukemia (AML) is occurring rapidly. Since 2017, nine agents have been approved for various indications in AML. These included several targeted therapies like venetoclax, FLT3 inhi
Guidelines on the initial diagnostic workup of acute leukemia (AL) have been issued by the College of American Pathologists and the American Society of Hematology (CAP/ASH). [118] Guidelines for the management of acute myeloid leukemia (AML) have been issued by the following organizations: Nat...
Transfusion to such concentrations should be avoided until the blast count has been reduced by early chemotherapy. 展开 关键词: MYELOID leukemia BLOOD -- Transfusion Treatment DOI: 10.1136/bmj.1.6121.1169 被引量: 79 年份: 1978 收藏 引用 批量引用 报错 分享 ...
The understanding of the molecular pathobiology of acute myeloid leukemia (AML) has spurred the identification of therapeutic targets and the development of corresponding novel targeted therapies. Since 2017, twelve agents have been approved for the treatment of AML subsets: the BCL2 inhibitor venetoclax...
Acute myeloid leukemia (AML) is fast-growing cancer that starts inside bone marrow, the soft tissue inside bones that helps form blood cells. The cancer grows from cells that would normally turn into white blood cells that help fight infection. ...
Little is known about how leukemia cells alter the bone marrow (BM) niche to facilitate their own growth and evade chemotherapy. Here, we provide evidence that acute myeloid leukemia (AML) blasts remodel the BM niche into a leukemia growth-permissive and normal hematopoiesis-suppressive microenvironm...